Targeted Antibodies for Cancer 2011

Venue: Etc. Venues Paddington

Location: London, United Kingdom

Event Date/Time: Aug 10, 2011 End Date/Time: Aug 11, 2011
Registration Date: Aug 10, 2011
Early Registration Date: May 10, 2011
Report as Spam


In recent years, targeted antibodies have emerged as playing a pivotal role in cancer therapeutics and are an increasingly important research area for the pharmaceutical, biotech and medical industries.

In such a fast-paced and competitive field, it is crucial for the key players to stay up-to date with the recent advances in antibody research and development.

TAC 2011 will address the critical scientific issues and challenges associated with developing targeted therapeutic antibodies for cancer. It will highlight improvements in antibody development, global trends and current clinical progress.

TAC 2011 has assembled an excellent programme of international experts including:
• Professor JJ Kain, Jain Pharmabiotech
• Dr Roman Kischel, Micromet AG
• Dr Horst Lindhofer, TRION Pharma
• Professor Melvyn Little, Affimed Therapeutics AG
• Dr Robert Lutz, ImmunoGen
• Dr Janice Reichert, Tufts Centre for the Study of Drug Development
• Dr David Satijn, Genmab
• Dr William Strohl, Johnson & Johnson

Whether you are an academic, oncology clinician or an industry professional in oncology, antibody development and manufacture, protein engineering, personalised medicine, biomarker discovery, drug/medicine safety or licensing/patenting of drugs, TAC 2011 will increase your knowledge and will provide you with practical advice that can positively influence your area of antibody research.

TAC 2011 will allow participants to:
• Gain insights into the latest trends in antibody therapeutics for cancer
• Join in the expert discussion about what biosimilars mean for the industry
• Understand the best strategies for improving antibody production
• Receive practical advice about taking antibodies from concept to reality with instructive case studies
• Examine how to capture the potential of personalised antibody therapies
• Assess the benefits of bispecific, trifunctional, radiolabelled and antibody-drug conjugates in the treatment of cancer
• Network and exchange ideas with the leading international experts and build up your business contacts


57 North Wharf Road
United Kingdom